Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
about
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensAdoptive T cell therapy: Addressing challenges in cancer immunotherapySorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Potential for immunotherapy in soft tissue sarcomaAdvances in the treatment of metastatic melanoma: adoptive T-cell therapyManufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapiesPre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapyBiochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cellsA phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaMitogenic stimulation of human tumor-infiltrating lymphocytes by secreted factor(s) from human tumor cell lines.CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway.Immunotherapeutic Intervention against Sarcomas.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte linesDistribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma.Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy.Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumorsLimited heterogeneity in the T-cell receptor V-gene usage in lymphocytes infiltrating human colorectal tumoursA phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanomaLysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibitionRecognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crestA phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma.Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes.Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens.Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell linesThe Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle.Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.Natural killer cells: immunobiology and clinical prospects.In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes.Identification of the promoter of the mouse obese gene.Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
P2860
Q24644442-BFF45996-96C2-46D2-8F10-71E4D3507296Q24805804-138CD6CC-19F5-4B77-92FC-A14507092704Q27002575-F24FC35D-5A96-400E-8467-50ACD7A634D0Q27008830-9207983C-8333-409C-8755-2F0CE3D7371EQ27027803-1A9E44AE-13E5-4D31-822E-CB4BC0831C23Q28085769-DFD610F3-A947-494C-82DA-26C73D0DD259Q28344557-FB1CD664-8A80-4203-97B5-D27C989133CCQ30442808-645362A0-0E85-41E9-BDA6-C5A06CE390A7Q30621114-2E6786E7-B242-49EA-AC9D-5FFB08CB2378Q33342339-1CCEE9C2-351B-4B12-9862-CB8F0E21520DQ33601843-999F2252-1648-4EC7-9C28-DBC7E4989DBDQ34063120-ECE09862-E36A-4CCD-A742-1513FDA7CFF0Q34188697-A9E744C6-AD34-4FD7-ADC4-F408B0130EA2Q34196481-5F384C17-F7B8-4DA9-9B32-193183426C4CQ34582987-3B792E85-29E6-49EE-8E0D-88E906033DE3Q35137387-3E7E7076-314B-41DC-B7DE-9BDDE35AB06DQ35570420-BE3FCAB7-E172-42BE-9A61-DB8C3ED5F01BQ35631979-64B479DC-B6DA-42E3-AD62-1E36341A488BQ35789284-FA2BEC72-DBF6-470B-9818-16C5B67C4436Q35822603-459009A2-2B80-4C36-BE80-30FC9E9FCDCBQ35945218-1A9D3D73-CA49-4B2D-96EA-E5B58D4192D8Q35979163-4F16B31B-A59C-4B97-8212-49109F86396BQ36080365-6459620C-A800-42BD-BFD3-91D9F1CF2EE5Q36165605-76223E71-C879-4317-80E6-233208E1C7E4Q36355725-C581FD95-D38F-40F4-9A3F-AE365399779DQ36361920-B84091FF-37C3-4413-9270-05976FEA1E6CQ36454475-944EA2D4-8A0A-467A-8DCF-C599B422434BQ36470250-A7AECCD1-4448-424B-960D-1C8645B65307Q36562370-E6D96EB2-3056-4B84-AE88-52E6DFC1B152Q36649855-6F80436B-3497-444D-BF30-CA20A84EEDD7Q36905613-0D60EFEB-1FF2-47CB-8FB2-89EBACEF5616Q36922798-998DF2DC-FB61-486D-9D9B-247ED7CF618CQ36923906-1275A169-0BEA-421C-9907-1C6CE9E87493Q36958449-1B948A56-9BDE-49EE-9C76-0F6B60D7ABB6Q37200886-0A855EB0-DAD1-4FF2-86E8-F38613E99BAAQ37220802-833BE725-3639-466E-86BF-4C00009EF696Q37350605-DC855379-8084-4AA3-BE78-F07E23D736BDQ37380356-04788AD5-FB10-40A1-A30E-56236E047389Q37629731-C9A3ACC4-2237-4190-BC72-EDA6C1BF2E57Q37629901-838636B3-B52C-4574-89D8-B5D5D90ACCAD
P2860
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
@en
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
@nl
type
label
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
@en
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
@nl
prefLabel
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
@en
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
@nl
P2093
P1476
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
@en
P2093
Rosenberg SA
Topalian SL
P304
P356
10.1016/S0022-1759(87)80018-2
P577
1987-08-01T00:00:00Z